Abstract | BACKGROUND: METHODS: The primary aim of this phase I trial was to verify the safety of low-dose NGR-hTNF combined with doxorubicin in treating refractory/resistant solid tumours. Secondary objectives included pharmacokinetics (PKs), pharmacodynamics, and clinical activity. In all 15 patients received NGR-hTNF (0.2-0.4-0.8-1.6 microg m(-2)) and doxorubicin (60-75 mg m(-2)), both given intravenously every 3 weeks. RESULTS: No dose-limiting toxicity occurred and the combination was well tolerated. Around two cases of neutropenic fevers, lasting 2 days, and two cases of cardiac ejection-fraction drops, one asymptomatic and the other symptomatic, were registered. Only 11% of the adverse events were related to NGR-hTNF and were short-lasting and mild-to-moderate in severity. There was no apparent PK interaction and the shedding of soluble TNF-receptors did not increase to 0.8 microg m(-2). One partial response (7%), at dose level 0.8 microg m(-2), and 10 stable diseases (66%), lasting for a median duration of 5.6 months, were observed. CONCLUSIONS:
|
Authors | V Gregorc, A Santoro, E Bennicelli, C J A Punt, G Citterio, J N H Timmer-Bonte, F Caligaris Cappio, A Lambiase, C Bordignon, C M L van Herpen |
Journal | British journal of cancer
(Br J Cancer)
Vol. 101
Issue 2
Pg. 219-24
(Jul 21 2009)
ISSN: 1532-1827 [Electronic] England |
PMID | 19568235
(Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study)
|
Chemical References |
- Recombinant Fusion Proteins
- Tumor Necrosis Factor-alpha
- tumor necrosis factor-alpha, CNGRC fusion protein, human
- Doxorubicin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, pharmacokinetics)
- Dose-Response Relationship, Drug
- Doxorubicin
(administration & dosage, adverse effects, pharmacokinetics)
- Female
- Humans
- Male
- Middle Aged
- Neoplasms
(drug therapy, metabolism)
- Recombinant Fusion Proteins
(administration & dosage, adverse effects, pharmacokinetics)
- Tumor Necrosis Factor-alpha
(administration & dosage, adverse effects, pharmacokinetics)
|